Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma - ScienceDirect
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Table of Contents page: Annals of Oncology
Studiehistorikk - Phase1
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Conceptual Framework for Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Cancer | American Society of Clinical Oncology Educational Book
PDF) New clinical trial designs in the era of Precision Medicine
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
First-in-human Phase I “Basket” Study of Debio 1347 (CH5183284), a Novel FGFR Inhibitor in Patients with FGFR Genomically
Phase 2 study of pembrolizumab in patients with advanced rare cancers | Journal for ImmunoTherapy of Cancer
Cancers | Free Full-Text | Changing Landscape of Systemic Therapy in Biliary Tract Cancer
New clinical trial designs in the era of precision medicine
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
2019 ASCO Annual Meeting Proceedings Immuno-Oncology Abstracts | Journal of Clinical Oncology
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Tumor‐agnostic inhibitors in oncology: A new phase for precision medicine - Li - 2020 - Journal of the Chinese Chemical Society - Wiley Online Library
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Is Debiopharm Group late reporting EU clinical trials?
Targeting FGFR inhibition in cholangiocarcinoma - ScienceDirect
Debio 1347-201 – Phase II basket trial in solid tumors harboring a fusion of FGFR1-3
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Life | Free Full-Text | Precision Medicine in Cholangiocarcinoma: Past, Present, and Future
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
